Free Trial

Ampio Pharmaceuticals (AMPE) Competitors

Ampio Pharmaceuticals logo
$0.0027 0.00 (0.00%)
As of 10/14/2025

AMPE vs. TRVN, ARDS, NAVB, EVLO, GNCAQ, GNCA, STAB, CMRA, PXMD, and EFTR

Should you be buying Ampio Pharmaceuticals stock or one of its competitors? The main competitors of Ampio Pharmaceuticals include Trevena (TRVN), Aridis Pharmaceuticals (ARDS), Navidea Biopharmaceuticals (NAVB), Evelo Biosciences (EVLO), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Statera Biopharma (STAB), Comera Life Sciences (CMRA), PaxMedica (PXMD), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "pharmaceutical products" industry.

Ampio Pharmaceuticals vs. Its Competitors

Trevena (NASDAQ:TRVN) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Trevena has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Comparatively, Ampio Pharmaceuticals has a beta of 5.13, indicating that its stock price is 413% more volatile than the S&P 500.

Ampio Pharmaceuticals has lower revenue, but higher earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Ampio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.03-$40.29M-$47.040.00
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.010.00

13.6% of Trevena shares are owned by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. 2.7% of Trevena shares are owned by company insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Trevena's average media sentiment score of 0.00 equaled Ampio Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Trevena Neutral
Ampio Pharmaceuticals Neutral

Trevena currently has a consensus price target of $5.00, indicating a potential upside of 41,566.67%. Given Trevena's stronger consensus rating and higher probable upside, equities analysts clearly believe Trevena is more favorable than Ampio Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trevena
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Ampio Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Ampio Pharmaceuticals N/A N/A N/A

Summary

Ampio Pharmaceuticals beats Trevena on 6 of the 10 factors compared between the two stocks.

Get Ampio Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMPE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMPE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

AMPE vs. The Competition

MetricAmpio PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$3K$1.01B$6.04B$21.90B
Dividend YieldN/A4.84%5.73%3.64%
P/E Ratio0.001.2785.1930.09
Price / SalesN/A176.74516.1665.31
Price / CashN/A17.6437.5723.91
Price / Book0.007.7812.424.70
Net Income-$8.63M-$7.59M$3.32B$1.01B
7 Day PerformanceN/A-1.26%0.80%-0.44%
1 Month PerformanceN/A26.02%10.52%1.44%
1 Year PerformanceN/A-10.05%76.14%15.00%

Ampio Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMPE
Ampio Pharmaceuticals
N/A$0.00
flat
N/A+22.7%$3KN/A0.0020
TRVN
Trevena
1.6444 of 5 stars
$0.01
flat
$5.00
+41,566.7%
-99.4%$12K$443K0.0040Gap Up
ARDS
Aridis Pharmaceuticals
N/A$0.00
flat
N/AN/A$11KN/A0.0030Gap Down
High Trading Volume
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13K0.0010
EVLO
Evelo Biosciences
N/A$0.00
flat
N/AN/A$9KN/A0.00120
GNCAQ
Genocea Biosciences
N/AN/AN/AN/A$6KN/A0.0070
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91M0.0070
STAB
Statera Biopharma
N/A$0.00
-50.0%
N/A-50.0%$5KN/A0.0020High Trading Volume
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00M0.002
PXMD
PaxMedica
N/AN/AN/A-99.9%$2KN/A0.002
EFTR
eFFECTOR Therapeutics
0.0559 of 5 stars
$0.00
flat
N/A-99.4%$1KN/A0.0010

Related Companies and Tools


This page (NYSE:AMPE) was last updated on 10/15/2025 by MarketBeat.com Staff
From Our Partners